Lyell Immunopharma, Inc. (LYEL) Form 8-K — Aug 6, 2026

$LYELForm 8-KItems 2.02, 9.01Filed Aug 6, 2026, 4:14 PM ET0001628280-26-054330Original filing

Lyell Immunopharma reported a second quarter 2026 GAAP net loss of $44.8 million, up $2.1 million from $42.7 million a year earlier, driven by a $4.7 million rise in R&D expense to $39.5 million on higher clinical trial activity and lower interest income. Non-GAAP net loss widened $2.8 million to $40.6 million. The company ended the quarter with $228.0 million in cash, cash equivalents and marketable securities, down from $247.2 million at year-end 2025, which management expects will fund operations into the third quarter of 2027.

Key figures

Revenue: $4 thousand (Q2 2026)
Net Income: -$44.8 million Q2 2026 GAAP net loss (vs -$42.7 million Q2 2025, a $2.1 million increase)
Total Assets: $311.2 million as of June 30, 2026
Cash Position: $228.0 million in cash, cash equivalents and marketable securities as of June 30, 2026 (vs $247.2 million as of December 31, 2025)
Ga expense: $9.6 million Q2 2026 (vs $9.8 million Q2 2025)
Rd expense: $39.5 million Q2 2026 (vs $34.9 million Q2 2025, +$4.7 million)
Cash runway: into Q3 2027
Lyl273 patients: 19 patients in U.S. Phase 1 (10 with GI prophylaxis, 9 without) as of May 5, 2026 cutoff
Non gaap net loss: -$40.6 million Q2 2026 (vs -$37.8 million Q2 2025, a $2.8 million increase)
Six month net loss: -$68.9 million H1 2026 (vs -$94.9 million H1 2025)
Stockholders equity: $233.8 million as of June 30, 2026
Prior year impairment: $1.4 million long-lived asset impairment charge in Q2 2025 that did not recur
Ronde cel patients treated: more than 100 R/R LBCL patients (65 in 3L+, 43 in 2L)
Lyl273 gi toxicity reduction: Grade >= 2 diarrhea or colitis reduced from 55% to 10% with GI prophylaxis
Put call fair value gain h1 2026: $17.6 million change in estimated fair value of securities purchase agreement put/call asset (excluded from non-GAAP)
Ronde cel manufacturing success rate: 97%

Price after filing

1 day: 0.0%7 days: +2.2%30 days: +6.8%

Close on the filing date to close N calendar days later (from $13.45). Historical, not a forecast.

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.